2Ichiyama T, Yoshitomi T, Nishikawa M, et al.NF-kappaB acti- vation in peripheral blood monocytes/macrophages and T cells during acute Kawasaki disease.Clin Immunol, 2001, 99: 373- 377.
3Bastian JF, Kushner HI, Miller E, et al.Sensitivity of the Kawasaki case definition for detecting coronary artery abnormalities.Presented at the 7th Intl.Kawasaki Disease Symposium, December, Hakone, Japan.2001.
4Bronstein DE, Dille AN, Austin JP, et al.Risk factors associated with Kawasaki disease in San Diego County.Pediatr Inf Dis J, 2000, 19: 1087- 1091.
5de Zorzi A, Colan SD, Gauvreau K, et al.Coronary artery di- mensions may be misclassified as normal in Kawasaki di- sease.J Pediatr, 1998, 133: 254- 258.
6Kato H, Sugimura T, Akagi T, et al.Long-term consequences of Kawasaki disease: 10～ 21-year follow-up study of 594 patients.Circulation, 1996, 94: 1379-1385.
7Gavin PJ, Crawford SE, Shulman ST, et al.Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease.Vasc Biol, 2003, 23: 576- 581.
8Chua PK, Melish ME, Yu Q, et al.Elevated levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteianse 1 during the acute phase of Kawasaki disease.Clin Diag Lab Immun, 2003, 10( 2): 308- 314.
9Li YY, McTieman CF, Feldman AM.Interplay of matrix meta- lloproteinases, tissue inhibitiors of metalloproteinases and their regulators in cardiac matrix remodeling.Cardiaovasc Res, 2000, 46( 2): 214- 224.
10Yanagawa H, Nakamura Y, Ojima T, et al.Changes in epidemic patterns of Kawasaki disease in Japan.Pediatr Infect Dis, 1999, 18: 64- 66.
